PMID- 28764219
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 2249-782X (Print)
IS  - 0973-709X (Electronic)
IS  - 0973-709X (Linking)
VI  - 11
IP  - 6
DP  - 2017 Jun
TI  - Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian 
      Patients with Type 2 Diabetes Mellitus in Real-Life Scenario.
PG  - OC22-OC25
LID - 10.7860/JCDR/2017/27013.10003 [doi]
AB  - INTRODUCTION: Teneligliptin is a recently developed Dipeptidyl Peptidase 4 (DPP4) 
      inhibitor. Teneligliptin is suitable for glycaemic control with renal impairment 
      including end stage renal disease. AIM: To assess the efficacy and safety of 
      teneligliptin in Asian Indian patients of Type 2 Diabetes Mellitus (T2DM) with 
      early Diabetic Kidney Disease (DKD). MATERIALS AND METHODS: This was a single 
      centre, retrospective analysis of patients with early DKD, who received 
      teneligliptin 20 mg once daily for 24 weeks. Data related to glycaemic 
      parameters, kidney function, lipid levels, retinopathy, neuropathy and safety 
      variables available at 12 and 24 weeks were analysed. Descriptive statistical 
      analysis was carried out. Statistical significance was assessed at a 5% level. 
      RESULTS: Total 37 patients (21 males; 16 females) were analysed. Compared to 
      baseline, significant reduction in Fasting Plasma Glucose (FPG) (mg/dl) 
      (143.89+/-28.26 vs. 125.78+/-20.52, p=0.001); Postprandial Glucose (PPG) (mg/dl) 
      (200.62+/-41.88 vs. 165.76+/-26.02, p=0.001); Glycated Haemoglobin (HbA1c) 
      (%)(8.65+/-0.58 vs. 8.17+/-0.54, p=0.001) was noted at 12 weeks. This trend was 
      further continued for 24 weeks with significant reduction in mean FPG, PPG and 
      HbA1c to 113.73+/-16.82 mg/ dl (p=0.008); 142.95+/-20.76 mg/dl (p=0.001); and 
      7.65+/-0.45% (p=0.001) respectively. Significant improvement in serum creatinine 
      (mg/dl) (2.45+/-0.27 vs. 2.26+/-0.23, p=0.001) and eGFR (CKD-EPI), (ml/min/1.73 m(2)) 
      (53.35+/-4.24 vs. 55.08+/-4.19, p=0.001) was noted at 12 weeks and continued for 24 
      weeks with reduction in serum creatinine of 0.37+/-0.18 mg/ dl (p=0.001) and 
      increase of eGFR of 4.60+/-1.59 ml/min/1.73 m(2) (p=0.001). At baseline, 
      proteinuria was noted in all patients while at 24 weeks, 40.5% (p=0.001) patients 
      did not report proteinuria. Significant improvements in lipid parameters with no 
      deterioration in retinopathy and subjective improvement in peripheral neuropathy 
      was also noted. No adverse events were noted. CONCLUSION: Teneligliptin reported 
      significant and sustained improvement in glycaemic control in Asian Indian 
      Patients of T2DM with early DKD and was well tolerated. Additionally, 
      Teneligliptin reported significant improvement in renal function.
FAU - Shah, Kiran
AU  - Shah K
AD  - Physician and Diabetologist, Diabetes and Thyroid Care Centre, Mumbai, 
      Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20170601
PL  - India
TA  - J Clin Diagn Res
JT  - Journal of clinical and diagnostic research : JCDR
JID - 101488993
PMC - PMC5535411
OTO - NOTNLM
OT  - Diabetic Nephropathies
OT  - Dipeptidyl Peptidase 4 Inhibitor
OT  - Retrospective studies
EDAT- 2017/08/03 06:00
MHDA- 2017/08/03 06:01
PMCR- 2017/08/01
CRDT- 2017/08/03 06:00
PHST- 2017/01/25 00:00 [received]
PHST- 2017/04/17 00:00 [accepted]
PHST- 2017/08/03 06:00 [entrez]
PHST- 2017/08/03 06:00 [pubmed]
PHST- 2017/08/03 06:01 [medline]
PHST- 2017/08/01 00:00 [pmc-release]
AID - 10.7860/JCDR/2017/27013.10003 [doi]
PST - ppublish
SO  - J Clin Diagn Res. 2017 Jun;11(6):OC22-OC25. doi: 10.7860/JCDR/2017/27013.10003. 
      Epub 2017 Jun 1.